Filing Flows › Abeona Therapeutics (ABEO) › Q2 2026
Abeona Therapeutics (ABEO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Abeona Therapeutics (ABEO) reported revenue of $11.4M for the second quarter 2026 (Q2 2026), up 28-fold from a year earlier and +31% from the quarter before. Operating margin was -120.0%, net loss $20.2M (177.4% of revenue).
Abeona Therapeutics, Q2 2026: revenue $11.4M (28× year over year), operating margin -120.0%, net loss $20.2M, operating cash flow −$17.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.4M | +31% | 28× |
| Operating profit | −$13.7M | — | — |
| Net earnings | −$20.2M | — | -119% |
| Operating cash flow | −$17.5M | — | — |
What changed
Revenue was $11.4M in Q2 2026, up 2745% year over year and up 31% from the previous quarter.
Operating costs exceeded revenue by $13.7M, an operating margin of -120.0%. Total costs grew 8% against revenue growth of 2745%. The quarter ended with a net loss of $20.2M, wider than the previous quarter's $17.1M loss.
Operating cash flow was −$17.5M. Non-cash charges added back $665K of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $479K exceeded it, leaving free cash flow of −$18.0M.
Questions
What was Abeona Therapeutics' revenue in the second quarter 2026?
Abeona Therapeutics (ABEO) reported revenue of $11.4M for the second quarter 2026 (Q2 2026), up 28-fold from a year earlier and +31% from the quarter before.
Was Abeona Therapeutics profitable in the second quarter 2026?
Operating loss was $13.7M (-120.0% of revenue) and net loss $20.2M.